Therapeutic effects of IkB kinase inhibitor during systemic inflammation

Int Immunopharmacol. 2020 Jul:84:106509. doi: 10.1016/j.intimp.2020.106509. Epub 2020 Apr 23.

Abstract

Animal models of inflammatory diseases support the idea that nuclear factor κB (NF-κB) activation plays a pathophysiological role and is widely implicated in multiple organ dysfunction (MOD). Indeed, the inhibition of the IκB kinase (IKK) complex, involved in the NF-κB pathway, can represent a promising approach to prevent MOD. The present work employed a rat model of systemic inflammation to investigate the preventive effects of Inhibitor of IKK complex (IKK16). In male Wistar rats, systemic inflammation was induced by a tail vein injection of lipopolysaccharides (LPS challenge; 12 mg/kg). Treatment with IKK16 (1 mg/kg body weight) was administered, by tail vein, 15 min post-LPS. Age- and sex-matched healthy rats and LPS rats without treatment were used as controls. At 24 h post-IKK16 treatment, serum enzyme levels indicative of liver, kidney, pancreas and muscle function were evaluated by biochemical analysis, and RT-PCR technique was used to analyze gene expression of pro-inflammatory cytokines. Hemodynamic parameters were also considered to assess the LPS-induced inflammation. IKK16 treatment yielded a strong therapeutic effect in preventing LPS-induced elevation of serological enzyme levels, attenuating hepatic, renal, pancreatic and muscular dysfunction after LPS challenge. Moreover, as expected, LPS promoted a significantly overexpression of TNF-α, IL-6 and IL-1β in the heart, kidney, and liver; which was diminished by IKK16 treatment. The present study provides convincing evidence that selective inhibition of the IκB kinase complex through the action of IKK16, plays a protective role against LPS-induced multiple organ dysfunction by reducing the acute inflammatory response induced by endotoxin exposure.

Keywords: IKK16; IκB kinase (IKK) complex; Lipopolysaccharide; Multiple organ dysfunction; Systemic inflammation.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use*
  • Baroreflex / drug effects
  • Blood Pressure / drug effects
  • Cytokines / genetics
  • Cytokines / immunology
  • Heart Rate / drug effects
  • I-kappa B Kinase / antagonists & inhibitors*
  • Inflammation / chemically induced
  • Inflammation / drug therapy*
  • Inflammation / immunology
  • Inflammation / physiopathology
  • Kidney / drug effects
  • Kidney / immunology
  • Lipopolysaccharides / pharmacology
  • Liver / drug effects
  • Liver / immunology
  • Male
  • Myocardium / immunology
  • Piperidines / pharmacology
  • Piperidines / therapeutic use*
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrrolidines / pharmacology
  • Pyrrolidines / therapeutic use*
  • Rats, Wistar

Substances

  • Anti-Inflammatory Agents
  • Cytokines
  • IkK-16 compound
  • Lipopolysaccharides
  • Piperidines
  • Protein Kinase Inhibitors
  • Pyrrolidines
  • I-kappa B Kinase